{"id":"pyrazinamide-oral-product","safety":{"commonSideEffects":[{"rate":"null","effect":"Hyperuricemia"},{"rate":"null","effect":"Gout"},{"rate":"null","effect":"Hepatotoxicity"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"},{"rate":"null","effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL614","moleculeType":"Small molecule","molecularWeight":"123.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pyrazinamide is a prodrug that requires activation by the mycobacterial enzyme pyrazinamidase to form pyrazinoic acid. The active metabolite inhibits the enzyme pantothenate synthetase and disrupts mycobacterial fatty acid synthesis, which is essential for cell wall integrity. This mechanism is particularly effective against intracellular and dormant Mycobacterium tuberculosis.","oneSentence":"Pyrazinamide is converted to pyrazinoic acid in mycobacteria, which disrupts bacterial cell wall synthesis and energy metabolism, leading to mycobacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:43.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy"}]},"trialDetails":[{"nctId":"NCT07073638","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis","status":"RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2025-10-13","conditions":"Pulmonary Tuberculoses","enrollment":24},{"nctId":"NCT07268664","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-12-01","conditions":"Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":120},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT06041919","phase":"PHASE2","title":"Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis","status":"TERMINATED","sponsor":"Thirty Respiratory Limited","startDate":"2023-09-27","conditions":"Rifampicin Susceptible Pulmonary Tuberculosis","enrollment":20},{"nctId":"NCT05221502","phase":"PHASE2","title":"Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-04-12","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06748937","phase":"PHASE2","title":"A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide","status":"RECRUITING","sponsor":"TASK Applied Science","startDate":"2025-03-03","conditions":"Tuberculosis","enrollment":60},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT04717908","phase":"NA","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2021-01-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":89},{"nctId":"NCT03867136","phase":"PHASE4","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-01","conditions":"Multidrug Resistant Tuberculosis","enrollment":354},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT04088019","phase":"","title":"Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-10-30","conditions":"Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction, Tuberculous Uveitis","enrollment":50},{"nctId":"NCT05401071","phase":"PHASE2, PHASE3","title":"Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-01-13","conditions":"Tuberculosis, Pulmonary","enrollment":2442},{"nctId":"NCT04721795","phase":"PHASE2, PHASE3","title":"Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","status":"COMPLETED","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2021-01-19","conditions":"Tuberculosis, Pulmonary, Tuberculosis","enrollment":150},{"nctId":"NCT03678688","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-18","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT03882177","phase":"PHASE2","title":"StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-21","conditions":"Tuberculosis, Pulmonary Tuberculosis","enrollment":16},{"nctId":"NCT05664568","phase":"PHASE2","title":"The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis","status":"UNKNOWN","sponsor":"Western Sydney Local Health District","startDate":"2023-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":30},{"nctId":"NCT04044001","phase":"PHASE1, PHASE2","title":"BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-11-15","conditions":"Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis","enrollment":77},{"nctId":"NCT02467608","phase":"PHASE2, PHASE3","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2012-12-06","conditions":"Pulmonary Tuberculosis","enrollment":557},{"nctId":"NCT05215990","phase":"PHASE1, PHASE2","title":"Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-01-15","conditions":"Tuberculosis, Pulmonary","enrollment":80},{"nctId":"NCT04629378","phase":"PHASE2","title":"Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-08-17","conditions":"Tuberculosis","enrollment":22},{"nctId":"NCT04387760","phase":"PHASE2","title":"Favipiravir vs Hydroxychloroquine vs Control in COVID -19","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-08-11","conditions":"SARS-CoV 2, COVID-19","enrollment":150},{"nctId":"NCT02454205","phase":"PHASE2, PHASE3","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2015-11-12","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis, Extensively-drug Resistant Tuberculosis","enrollment":154},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02684240","phase":"PHASE2","title":"A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2016-02","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT00816426","phase":"PHASE1","title":"Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-12-29","conditions":"Tuberculosis","enrollment":19},{"nctId":"NCT03563599","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","status":"COMPLETED","sponsor":"Qurient Co., Ltd.","startDate":"2018-07-23","conditions":"Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB","enrollment":60},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT02193776","phase":"PHASE2","title":"A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-10-23","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT02342886","phase":"PHASE3","title":"Shortening Treatment by Advancing Novel Drugs","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-02","conditions":"Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant","enrollment":284},{"nctId":"NCT02279875","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-11","conditions":"Pulmonary Tuberculosis","enrollment":113},{"nctId":"NCT01516203","phase":"PHASE2","title":"Phase 2a EBA Trial of AZD5847","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-12-05","conditions":"Tuberculosis","enrollment":75},{"nctId":"NCT01498419","phase":"PHASE2","title":"Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2012-03","conditions":"Pulmonary Tuberculosis","enrollment":207},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT02975570","phase":"PHASE3","title":"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2017-08","conditions":"Tuberculosis Multi Drug Resistant Active","enrollment":""},{"nctId":"NCT02169882","phase":"PHASE2, PHASE3","title":"High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2014-12-01","conditions":"Tuberculosis, Meningeal","enrollment":60},{"nctId":"NCT01399788","phase":"PHASE1","title":"A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT02901288","phase":"PHASE4","title":"Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2016-08","conditions":"Tuberculosis, Pulmonary","enrollment":3900},{"nctId":"NCT00771498","phase":"PHASE4","title":"An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2008-11","conditions":"HIV Infection, Tuberculosis","enrollment":30},{"nctId":"NCT02121314","phase":"PHASE2","title":"HRZE Fasted/Fed in Newly Diagnosed TB","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2013-07","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT01785927","phase":"PHASE1","title":"The Safety of Tuberculosis Treatments by Oral Inhalation","status":"UNKNOWN","sponsor":"Prince of Songkla University","startDate":"2013-02","conditions":"Healthy","enrollment":40},{"nctId":"NCT01158755","phase":"PHASE2","title":"Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2010-10","conditions":"Meningitis, Tuberculous, Pharmacokinetics, Pharmacodynamics","enrollment":60},{"nctId":"NCT00948077","phase":"NA","title":"Pharmacokinetic Study for Anti-tuberculosis Drugs","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2009-07","conditions":"Pulmonary Tuberculosis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pyrazinamide Oral Product","genericName":"Pyrazinamide Oral Product","companyName":"Wits Health Consortium (Pty) Ltd","companyId":"wits-health-consortium-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pyrazinamide is converted to pyrazinoic acid in mycobacteria, which disrupts bacterial cell wall synthesis and energy metabolism, leading to mycobacterial cell death. Used for Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}